A carregar...
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
On October 2, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab, a breakthrough therapy-designated drug, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express programmed death-ligand 1 (PD-L1), as determin...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4861368/ https://ncbi.nlm.nih.gov/pubmed/27026676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0498 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|